Financials data is unavailable for this security.
View more
Year on year Arcturus Therapeutics Holdings Inc 's revenues fell -19.03% from 206.00m to 166.80m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 9.35m to a loss of 29.73m.
| Gross margin | -- |
|---|---|
| Net profit margin | -39.05% |
| Operating margin | -50.22% |
| Return on assets | -15.13% |
|---|---|
| Return on equity | -23.12% |
| Return on investment | -18.67% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Arcturus Therapeutics Holdings Inc fell by 45.09m. Cash Flow from Investing was negative at 2.90m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 18.10m for operations while cash used for financing totalled 24.09m.
| Cash flow per share | -2.19 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.67 |
|---|---|
| Tangible book value per share | 9.67 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.76 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
